• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗病毒性疾病的纳米医学:解决大问题的更小方案。

Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems.

作者信息

Ghorai Suvankar, Shand Harshita, Patra Soumendu, Panda Kingshuk, Santiago Maria J, Rahman Md Sohanur, Chinnapaiyan Srinivasan, Unwalla Hoshang J

机构信息

Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.

Department of Microbiology, Raiganj University, Raiganj 733134, India.

出版信息

Pharmaceutics. 2024 Mar 16;16(3):407. doi: 10.3390/pharmaceutics16030407.

DOI:10.3390/pharmaceutics16030407
PMID:38543301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10975899/
Abstract

The continuous evolution of new viruses poses a danger to world health. Rampant outbreaks may advance to pandemic level, often straining financial and medical resources to breaking point. While vaccination remains the gold standard to prevent viral illnesses, these are mostly prophylactic and offer minimal assistance to those who have already developed viral illnesses. Moreover, the timeline to vaccine development and testing can be extensive, leading to a lapse in controlling the spread of viral infection during pandemics. Antiviral therapeutics can provide a temporary fix to tide over the time lag when vaccines are not available during the commencement of a disease outburst. At times, these medications can have negative side effects that outweigh the benefits, and they are not always effective against newly emerging virus strains. Several limitations with conventional antiviral therapies may be addressed by nanotechnology. By using nano delivery vehicles, for instance, the pharmacokinetic profile of antiviral medications can be significantly improved while decreasing systemic toxicity. The virucidal or virus-neutralizing qualities of other special nanomaterials can be exploited. This review focuses on the recent advancements in nanomedicine against RNA viruses, including nano-vaccines and nano-herbal therapeutics.

摘要

新病毒的不断演变对世界卫生构成威胁。猖獗的疫情可能升级为大流行,常常使财政和医疗资源紧张到极限。虽然接种疫苗仍然是预防病毒性疾病的金标准,但这些大多是预防性的,对那些已经感染病毒性疾病的人帮助甚微。此外,疫苗研发和测试的时间线可能很长,导致在大流行期间控制病毒感染传播出现滞后。抗病毒疗法可以提供一个临时解决方案,以度过疾病爆发初期没有疫苗可用的时间差。有时,这些药物的副作用可能超过其益处,而且它们并不总是对新出现的病毒株有效。传统抗病毒疗法的一些局限性可以通过纳米技术来解决。例如,通过使用纳米递送载体,可以显著改善抗病毒药物的药代动力学特征,同时降低全身毒性。还可以利用其他特殊纳米材料的杀病毒或病毒中和特性。本综述重点关注纳米医学在对抗RNA病毒方面的最新进展,包括纳米疫苗和纳米草药疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3a0/10975899/5efd0741fa8c/pharmaceutics-16-00407-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3a0/10975899/a776a2caeeb6/pharmaceutics-16-00407-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3a0/10975899/b1ebec1c3989/pharmaceutics-16-00407-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3a0/10975899/bb2127c46470/pharmaceutics-16-00407-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3a0/10975899/5efd0741fa8c/pharmaceutics-16-00407-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3a0/10975899/a776a2caeeb6/pharmaceutics-16-00407-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3a0/10975899/b1ebec1c3989/pharmaceutics-16-00407-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3a0/10975899/bb2127c46470/pharmaceutics-16-00407-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3a0/10975899/5efd0741fa8c/pharmaceutics-16-00407-g004.jpg

相似文献

1
Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems.用于治疗病毒性疾病的纳米医学:解决大问题的更小方案。
Pharmaceutics. 2024 Mar 16;16(3):407. doi: 10.3390/pharmaceutics16030407.
2
Nanotechnology for virus treatment.用于病毒治疗的纳米技术。
Nano Today. 2021 Feb;36:101031. doi: 10.1016/j.nantod.2020.101031. Epub 2020 Dec 1.
3
Nanotechnology-based antiviral therapeutics.基于纳米技术的抗病毒疗法。
Drug Deliv Transl Res. 2021 Jun;11(3):748-787. doi: 10.1007/s13346-020-00818-0.
4
Nanotechnology: an evidence-based analysis.纳米技术:基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1.
5
Advancements in protein nanoparticle vaccine platforms to combat infectious disease.蛋白质纳米颗粒疫苗平台在传染病防治方面的进展。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 May;13(3):e1681. doi: 10.1002/wnan.1681. Epub 2020 Nov 8.
6
Nanotechnology for COVID-19: Therapeutics and Vaccine Research.纳米技术在新冠病毒防治中的应用:治疗方法和疫苗研究。
ACS Nano. 2020 Jul 28;14(7):7760-7782. doi: 10.1021/acsnano.0c04006. Epub 2020 Jun 29.
7
Nano-based approaches in the development of antiviral agents and vaccines.基于纳米的抗病毒药物和疫苗的研发方法。
Life Sci. 2021 Jan 15;265:118761. doi: 10.1016/j.lfs.2020.118761. Epub 2020 Nov 12.
8
Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.重新定位,也要(纳米)重塑!纳米医学在抗击 SARS-CoV2 中的潜在作用。
J Control Release. 2021 Sep 10;337:258-284. doi: 10.1016/j.jconrel.2021.07.028. Epub 2021 Jul 20.
9
Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.纳米医学在 SARS-CoV-2 中的应用:现状与未来展望。
Int J Nanomedicine. 2021 Jan 22;16:539-560. doi: 10.2147/IJN.S283686. eCollection 2021.
10
Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).纳米技术在防治病毒相关呼吸道传染病(VARID)的药物和疫苗传递方面的新进展。
Int J Mol Sci. 2021 Jun 28;22(13):6937. doi: 10.3390/ijms22136937.

引用本文的文献

1
Treatment of lung diseases nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments?肺部疾病的治疗——纳米颗粒与纳米机器人:它们是克服现有治疗方法的可行替代方案吗?
Mater Today Bio. 2025 Feb 26;31:101616. doi: 10.1016/j.mtbio.2025.101616. eCollection 2025 Apr.
2
Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)及其变体的功能设计纳米疫苗。
Vaccines (Basel). 2024 Jul 12;12(7):764. doi: 10.3390/vaccines12070764.

本文引用的文献

1
Anti-Viral Surfaces in the Fight against the Spread of Coronaviruses.对抗冠状病毒传播的抗病毒表面
Membranes (Basel). 2023 Apr 27;13(5):464. doi: 10.3390/membranes13050464.
2
Potential Regulation of NF-κB by Curcumin in Coronavirus-Induced Cytokine Storm and Lung Injury.姜黄素对冠状病毒诱导的细胞因子风暴和肺损伤中NF-κB的潜在调节作用
Int J Prev Med. 2022 Dec 26;13:156. doi: 10.4103/ijpvm.IJPVM_565_20. eCollection 2022.
3
Modern Herbal Nanogels: Formulation, Delivery Methods, and Applications.现代草药纳米凝胶:制剂、给药方法及应用
Gels. 2022 Feb 7;8(2):97. doi: 10.3390/gels8020097.
4
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.一种用于诱导重组 SARS-CoV-2 蛋白疫苗产生有效抗病毒免疫应答的联合佐剂。
Front Immunol. 2021 Sep 16;12:729189. doi: 10.3389/fimmu.2021.729189. eCollection 2021.
5
Lactoferrin may inhibit the development of cancer via its immunostimulatory and immunomodulatory activities (Review).乳铁蛋白可能通过其免疫刺激和免疫调节活性抑制癌症的发展(综述)。
Int J Oncol. 2021 Nov;59(5). doi: 10.3892/ijo.2021.5265. Epub 2021 Sep 17.
6
Bioactive Compounds as Potential Agents for Sexually Transmitted Diseases Management: A Review to Explore Molecular Mechanisms of Action.生物活性化合物作为性传播疾病管理的潜在药物:探索作用分子机制的综述
Front Pharmacol. 2021 Aug 24;12:674682. doi: 10.3389/fphar.2021.674682. eCollection 2021.
7
Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial.口服纳米姜黄素制剂治疗轻至中度门诊COVID-19的疗效:一项随机三盲安慰剂对照临床试验。
Food Sci Nutr. 2021 Jun 19;9(8):4068-4075. doi: 10.1002/fsn3.2226. eCollection 2021 Aug.
8
Nanoscience and quantum science-led biocidal and antiviral strategies.纳米科学和量子科学引领的杀菌和抗病毒策略。
J Mater Chem B. 2021 Sep 22;9(36):7328-7346. doi: 10.1039/d0tb02639e.
9
Strawberry and Ginger Silver Nanoparticles as Potential Inhibitors for SARS-CoV-2 Assisted by In Silico Modeling and Metabolic Profiling.草莓和姜银纳米颗粒作为严重急性呼吸综合征冠状病毒2潜在抑制剂的计算机模拟和代谢谱分析辅助研究
Antibiotics (Basel). 2021 Jul 6;10(7):824. doi: 10.3390/antibiotics10070824.
10
Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.工程化当前核苷修饰的 mRNA-LNP 疫苗以对抗 SARS-CoV-2。
Biomed Pharmacother. 2021 Oct;142:111953. doi: 10.1016/j.biopha.2021.111953. Epub 2021 Jul 23.